Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carol Moreno

Showing results (151-160 of 167) with videos related to

Pageof 17
Sort By:
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 1, 2012
Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbitsKatharina Katter, Aron M Geurts, Orsolya Hoffmann, et al.
British Journal of Haematology|June 8, 2017
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)Johannes Schetelig, Liesbeth C de Wreede, Niels S Andersen, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Cancers|August 12, 2022
<i>TP53</i> Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex KaryotypeSilvia Ramos-Campoy, Anna Puiggros, Joanna Kamaso, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic LeukemiaThomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2016
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Mehdi Hamadani, et al.
Hematological Oncology|October 3, 2022
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemiaRiccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, et al.
Oncotarget|September 15, 2017
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM FISH</i> deletionsAnna Puiggros, Rosa Collado, Maria José Calasanz, et al.
Pageof 17

Showing results (151-160 of 167) with videos related to

Sort By:
Pageof 17
Blood|March 8, 2019
Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumabJohn C Byrd, Peter Hillmen, Susan O'Brien, et al.
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|December 1, 2012
Transposon-mediated transgenesis, transgenic rescue, and tissue-specific gene expression in rodents and rabbitsKatharina Katter, Aron M Geurts, Orsolya Hoffmann, et al.
British Journal of Haematology|June 8, 2017
Centre characteristics and procedure-related factors have an impact on outcomes of allogeneic transplantation for patients with CLL: a retrospective analysis from the European Society for Blood and Marrow Transplantation (EBMT)Johannes Schetelig, Liesbeth C de Wreede, Niels S Andersen, et al.
American Journal of Hematology|August 22, 2018
Single-agent ibrutinib versus chemoimmunotherapy regimens for treatment-naïve patients with chronic lymphocytic leukemia: A cross-trial comparison of phase 3 studiesTadeusz Robak, Jan A Burger, Alessandra Tedeschi, et al.
Cancers|August 12, 2022
<i>TP53</i> Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex KaryotypeSilvia Ramos-Campoy, Anna Puiggros, Joanna Kamaso, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 27, 2019
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic LeukemiaThomas J Kipps, Graeme Fraser, Steven E Coutre, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 26, 2018
Improvement in Parameters of Hematologic and Immunologic Function and Patient Well-being in the Phase III RESONATE Study of Ibrutinib Versus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaJacqueline C Barrientos, Susan O'Brien, Jennifer R Brown, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 24, 2016
Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow TransplantationMohamed A Kharfan-Dabaja, Ambuj Kumar, Mehdi Hamadani, et al.
Hematological Oncology|October 3, 2022
Long-term benefit of IGHV mutated patients in a real-life multicenter cohort of FCR-treated chronic lymphocytic leukemiaRiccardo Moia, Riccardo Dondolin, Maria Stefania De Propris, et al.
Oncotarget|September 15, 2017
Patients with chronic lymphocytic leukemia and complex karyotype show an adverse outcome even in absence of <i>TP53/ATM FISH</i> deletionsAnna Puiggros, Rosa Collado, Maria José Calasanz, et al.
Pageof 17